a study on Melanoma Skin Cancer/Melanoma Medullary Thyroid Cancer Glioblastoma Large Cell Neuroendocrine Carcinoma Prostate Cancer Gastroenteropancreatic Neuroendocrine Carcinoma Other Neuroendocrine Carcinoma Solid Tumor
To assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
This is a multicenter, open-label study involving multiple specific advanced solid tumor types, consisting of a dose escalation Part A followed by an expansion Part B. Cancer subtypes will be studied in separate disease-specific cohorts in both Parts. Eight separate cohorts will enroll malignant melanoma, medullary thyroid cancer (MTC), glioblastoma, large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic (GEP), neuroendocrine carcinoma (NEC), other NEC, and solid tumors other than the above.
Malignant Melanoma Medullary Thyroid Cancer Glioblastoma Large Cell Neuroendocrine Carcinoma Neuroendocrine Prostate Cancer High Grade Gastroenteropancreatic Neuroendocrine Carcinoma Other Neuroendocrine Carcinoma Other Solid Tumors
Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:
T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression).
Recent or ongoing serious infection, including:
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02709889.
© 2017 The Regents of the University of California